Top

memo - Magazine of European Medical Oncology

Published in:

Open Access 01-06-2019 | Computed Tomography | short review

Challenges in implementation of lung cancer screening—radiology requirements

Author: Gerlig Widmann, MD, PD, MSc, EBIR

Published in: memo - Magazine of European Medical Oncology | Issue 2/2019

Summary

Implementation of lung cancer screening is a challenge for radiology. The present short review summarizes major requirements which are needed to ensure high rates of diagnostic accuracy and appropriate protocols for follow-up and invasive work-up. Standardization of procedures, structured reporting, assessment of quality metrics, close multidisciplinary collaboration, and continuous education are essential. Additional quantification of coronary artery calcium and emphysema may provide synergistic medical benefits for a lung cancer screening programme.

National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PMSJ. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. https://doi.org/10.1056/NEJMoa1102873.CrossRef

Huo J, Xu Y, Sheu T, Volk RJ, Shih Y‑CT. Complication rates and downstream medical costs associated with invasive diagnostic procedures for lung abnormalities in the community setting. Jama Intern Med. 2019; https://doi.org/10.1001/jamainternmed.2018.6277.CrossRefPubMed

Fintelmann FJ, Bernheim A, Digumarthy SR, Lennes IT, Kalra MK, Gilman MD, et al. The 10 pillars of lung cancer screening: rationale and logistics of a lung cancer screening program. Radiographics. 2015;35(7):1893–908. https://doi.org/10.1148/rg.2015150079.CrossRefPubMed

Bankier AA, MacMahon H, Goo JM, Rubin GD, Schaefer-Prokop CM, Naidich DP. Recommendations for measuring pulmonary nodules at CT: a statement from the Fleischner society. Radiology. 2017;285(2):584–600. https://doi.org/10.1148/radiol.2017162894.CrossRefPubMed

Kazerooni EA, Austin JHM, Black WC, Dyer DS, Hazelton TR, Leung AN, et al. ACR-STR practice parameter for the performance and reporting of lung cancer screening thoracic computed tomography (CT). J Thorac Imaging. 2014;29(5):310–6. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00005382-201409000-00012.CrossRef

Zhao YR, Xie X, De Koning HJ, Mali WP, Vliegenthart R, Oudkerk M. NELSON lung cancer screening study. Cancer Imaging. 2011;11(SPEC. ISS. A):79–84.CrossRef

Hu-Wang E, Schuzer JL, Rollison S, Leifer ES, Steveson C, Gopalakrishnan V, et al. Chest CT scan at radiation dose of a Posteroanterior and lateral chest radiograph series. 2018. https://linkinghub.elsevier.com/retrieve/pii/S0012369218324875..

Pinsky PF, Gierada DS, Black W, Munden R, Nath H, Aberle D, et al. Performance of lung-RADS in the national lung screening trial. Ann Intern Med. 2015;162(7):485. https://doi.org/10.7326/M14-2086.CrossRefPubMedPubMedCentral

Xu DM, Gietema H, de Koning H, Vernhout R, Nackaerts K, Prokop M, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Cancer Treat Res. 2006;54(2):177–84.

10.

Glodny B, Schönherr E, Freund MC, Haslauer M, Petersen J, Loizides A, et al. Measures to prevent air embolism in transthoracic biopsy of the lung. AJR Am J Roentgenol. 2017;208(5):W184–W91.CrossRef

11.

Nguyen XV, Davies L, Eastwood JD, Hoang JK. Extrapulmonary findings and malignancies in participants screened with chest CT in the national lung screening trial. J Am Coll Radiol. 2017;14(3):324–30.CrossRef

12.

Hecht HS. Coronary artery calcium scanning: past, present, and future. Jacc Cardiovasc Imaging. 2015;8(5):579–96.CrossRef

13.

Hecht HS, Blaha MJ, Kazerooni EA, Cury RC, Budoff M, Leipsic J, et al. CAC-DRS: coronary artery calcium data and reporting system. An expert consensus document of the society of cardiovascular computed Tomography (SCCT). J Cardiovasc Comput Tomogr. 2018;12(3):185–91.CrossRef

14.

Xie X, Zhao Y, De Bock GH, De Jong PA, Mali WP, Oudkerk M, et al. Validation and prognosis of coronary artery calcium scoring in nontriggered thoracic computed tomography: Systematic review and meta-analysis. Circ Cardiovasc Imaging. 2013;6:514–21.CrossRef

15.

Fan L, Fan K. Lung cancer screening CT-based coronary artery calcification in predicting cardiovascular events: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(20):e10461. https://doi.org/10.1097/MD.0000000000010461.CrossRef

16.

Takx RAP, Vliegenthart R, Hoesein FAAM, Išgum I, de Koning HJ, Mali WPTM, et al. Pulmonary function and CT biomarkers as risk factors for cardiovascular events in male lung cancer screening participants: the NELSON study. Eur Radiol. 2015;25(1):65–71.CrossRef

17.

Cressman S, Peacock SJ, Tammemägi MC, Evans WK, Leighl NB, Goffin JR, et al. The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency. J Thorac Oncol. 2017;12(8):1210–22.CrossRef

18.

Mouronte-Roibás C, Leiro-Fernández V, Fernández-Villar A, Botana-Rial M, Ramos-Hernández C, Ruano-Ravina A. COPD, emphysema and the onset of lung cancer. A systematic review. Cancer Lett. 2016;382:240–4.CrossRef

19.

Mets OM, Schmidt M, Buckens CF, Gondrie MJ, Isgum I, Oudkerk M, et al. Diagnosis of chronic obstructive pulmonary disease in lung cancer screening Computed Tomography scans: Independent contribution of emphysema, air trapping and bronchial wall thickening. Respir Res. 2013;14:59. https://doi.org/10.1186/1465-9921-14-59.CrossRefPubMedPubMedCentral

Title: Challenges in implementation of lung cancer screening—radiology requirements
Author: Gerlig Widmann, MD, PD, MSc, EBIR
Publication date: 01-06-2019
Publisher: Springer Vienna
Keywords: Computed Tomography
Lung Cancer
Computed Tomography
Lung Cancer
Pulmonary Nodule
Lung Cancer
Published in: memo - Magazine of European Medical Oncology / Issue 2/2019
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-019-0490-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 2/2019

Resistance in gastrointestinal stromal tumors

Tobacco control: prevention and cessation in Europe

Obituary for Professor Michael Steurer

memo—publisher’s report 2018

Whom to screen? A view on lung cancer screening from the pneumologist’s perspective

Lung cancer screening from the oncologist’s perspective

Keynote webinar | Spotlight on antibody–drug conjugates in cancer